Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients

Eiko Yamada, Ritsuo Takagi, Yoshinari Tanabe, Hiroshi Fujiwara, Naoki Hasegawa, Shingo Kato

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: We studied the relationships between plasma and saliva concentrations of antiretroviral drugs to explore whether saliva can be used for therapeutic drug monitoring (TDM). Methods: Abacavir (ABC), tenofovir (TFV), darunavir (DRV), and raltegravir (RAL) in plasma and saliva from 30 HIV-1-infected patients were quantified using liquid chromatography-tandem mass spectrometry. Results: Mean salivato- plasma concentration ratios were 0.623 (ABC), 0.024 (TFV), 0.065 (DRV), and 0.0135 (RAL), which agree with the plasma protein binding rates except TFV. Significant correlations were evident between saliva and plasma concentrations of ABC, DRV, and RAL. Conclusions: This study suggests that plasma concentrations of ABC, DRV, and RAL can be estimated from their saliva concentrations and that the saliva concentration of some antiretroviral drugs reflects the unbound drug concentration in plasma.

Original languageEnglish
Pages (from-to)567-570
Number of pages4
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume55
Issue number7
DOIs
Publication statusPublished - 2017

Fingerprint

Tenofovir
Saliva
HIV-1
Pharmaceutical Preparations
Drug Monitoring
Tandem Mass Spectrometry
Protein Binding
Liquid Chromatography
Raltegravir Potassium
abacavir
Darunavir
Blood Proteins

Keywords

  • Antiretroviral therapy
  • HIV-1 infection
  • Pre-exposure prophylaxis
  • Saliva
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology
  • Pharmacology (medical)

Cite this

Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients. / Yamada, Eiko; Takagi, Ritsuo; Tanabe, Yoshinari; Fujiwara, Hiroshi; Hasegawa, Naoki; Kato, Shingo.

In: International Journal of Clinical Pharmacology and Therapeutics, Vol. 55, No. 7, 2017, p. 567-570.

Research output: Contribution to journalArticle

Yamada, Eiko ; Takagi, Ritsuo ; Tanabe, Yoshinari ; Fujiwara, Hiroshi ; Hasegawa, Naoki ; Kato, Shingo. / Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients. In: International Journal of Clinical Pharmacology and Therapeutics. 2017 ; Vol. 55, No. 7. pp. 567-570.
@article{0880540b15de48c696aefb262e8659d7,
title = "Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients",
abstract = "Objective: We studied the relationships between plasma and saliva concentrations of antiretroviral drugs to explore whether saliva can be used for therapeutic drug monitoring (TDM). Methods: Abacavir (ABC), tenofovir (TFV), darunavir (DRV), and raltegravir (RAL) in plasma and saliva from 30 HIV-1-infected patients were quantified using liquid chromatography-tandem mass spectrometry. Results: Mean salivato- plasma concentration ratios were 0.623 (ABC), 0.024 (TFV), 0.065 (DRV), and 0.0135 (RAL), which agree with the plasma protein binding rates except TFV. Significant correlations were evident between saliva and plasma concentrations of ABC, DRV, and RAL. Conclusions: This study suggests that plasma concentrations of ABC, DRV, and RAL can be estimated from their saliva concentrations and that the saliva concentration of some antiretroviral drugs reflects the unbound drug concentration in plasma.",
keywords = "Antiretroviral therapy, HIV-1 infection, Pre-exposure prophylaxis, Saliva, Therapeutic drug monitoring",
author = "Eiko Yamada and Ritsuo Takagi and Yoshinari Tanabe and Hiroshi Fujiwara and Naoki Hasegawa and Shingo Kato",
year = "2017",
doi = "10.5414/CP202789",
language = "English",
volume = "55",
pages = "567--570",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "7",

}

TY - JOUR

T1 - Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients

AU - Yamada, Eiko

AU - Takagi, Ritsuo

AU - Tanabe, Yoshinari

AU - Fujiwara, Hiroshi

AU - Hasegawa, Naoki

AU - Kato, Shingo

PY - 2017

Y1 - 2017

N2 - Objective: We studied the relationships between plasma and saliva concentrations of antiretroviral drugs to explore whether saliva can be used for therapeutic drug monitoring (TDM). Methods: Abacavir (ABC), tenofovir (TFV), darunavir (DRV), and raltegravir (RAL) in plasma and saliva from 30 HIV-1-infected patients were quantified using liquid chromatography-tandem mass spectrometry. Results: Mean salivato- plasma concentration ratios were 0.623 (ABC), 0.024 (TFV), 0.065 (DRV), and 0.0135 (RAL), which agree with the plasma protein binding rates except TFV. Significant correlations were evident between saliva and plasma concentrations of ABC, DRV, and RAL. Conclusions: This study suggests that plasma concentrations of ABC, DRV, and RAL can be estimated from their saliva concentrations and that the saliva concentration of some antiretroviral drugs reflects the unbound drug concentration in plasma.

AB - Objective: We studied the relationships between plasma and saliva concentrations of antiretroviral drugs to explore whether saliva can be used for therapeutic drug monitoring (TDM). Methods: Abacavir (ABC), tenofovir (TFV), darunavir (DRV), and raltegravir (RAL) in plasma and saliva from 30 HIV-1-infected patients were quantified using liquid chromatography-tandem mass spectrometry. Results: Mean salivato- plasma concentration ratios were 0.623 (ABC), 0.024 (TFV), 0.065 (DRV), and 0.0135 (RAL), which agree with the plasma protein binding rates except TFV. Significant correlations were evident between saliva and plasma concentrations of ABC, DRV, and RAL. Conclusions: This study suggests that plasma concentrations of ABC, DRV, and RAL can be estimated from their saliva concentrations and that the saliva concentration of some antiretroviral drugs reflects the unbound drug concentration in plasma.

KW - Antiretroviral therapy

KW - HIV-1 infection

KW - Pre-exposure prophylaxis

KW - Saliva

KW - Therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=85021275147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021275147&partnerID=8YFLogxK

U2 - 10.5414/CP202789

DO - 10.5414/CP202789

M3 - Article

VL - 55

SP - 567

EP - 570

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 7

ER -